- Home
- TRVI vs XNCR Comparison
TRVI vs XNCR Comparison
Compare TRVI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- XNCR
- Stock Information
- Founded
- TRVI 2011
- XNCR 1997
- Country
- TRVI United States
- XNCR United States
- Employees
- TRVI N/A
- XNCR N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- XNCR Health Care
- Exchange
- TRVI Nasdaq
- XNCR Nasdaq
- Market Cap
- TRVI 629.8M
- XNCR 579.3M
- IPO Year
- TRVI 2019
- XNCR 2013
- Fundamental
- Price
- TRVI $5.83
- XNCR $8.38
- Analyst Decision
- TRVI Strong Buy
- XNCR Buy
- Analyst Count
- TRVI 8
- XNCR 8
- Target Price
- TRVI $19.31
- XNCR $29.29
- AVG Volume (30 Days)
- TRVI 1.0M
- XNCR 1.1M
- Earning Date
- TRVI 05-08-2025
- XNCR 05-07-2025
- Dividend Yield
- TRVI N/A
- XNCR N/A
- EPS Growth
- TRVI N/A
- XNCR N/A
- EPS
- TRVI N/A
- XNCR N/A
- Revenue
- TRVI N/A
- XNCR $127,228,000.00
- Revenue This Year
- TRVI N/A
- XNCR N/A
- Revenue Next Year
- TRVI N/A
- XNCR $27.37
- P/E Ratio
- TRVI N/A
- XNCR N/A
- Revenue Growth
- TRVI N/A
- XNCR N/A
- 52 Week Low
- TRVI $2.30
- XNCR $7.16
- 52 Week High
- TRVI $7.39
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- TRVI 56.14
- XNCR 41.78
- Support Level
- TRVI $6.08
- XNCR $7.34
- Resistance Level
- TRVI $6.47
- XNCR $7.99
- Average True Range (ATR)
- TRVI 0.39
- XNCR 0.47
- MACD
- TRVI -0.00
- XNCR 0.08
- Stochastic Oscillator
- TRVI 45.06
- XNCR 45.91
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.